Table 1.
Erlotinib | KSFM1 | w/o EGF | ||||
---|---|---|---|---|---|---|
HCX-1 | HCX-2 | HCX-3 | HCX-1 | HCX-2 | HCX-3 | |
untreated | 6/62 | 6/6 | 5/5 | 6/6 | 6/6 | 6/6 |
0.1 μM | 5/6 | 3/6 | 5/6 | 0/5 | 0/6 | 0/6 |
0.3 μM | 2/5 | 0/5 | 0/6 | 0/5 | 0/6 | 0/6 |
1.0 μM | 0/6 | 0/6 | 0/6 | 0/6 | 0/5 | 0/6 |
Immortalization assays were performed in KSFM with 5 ng/ml EGF (3 left columns) or KSFM without EGF (3 right columns). Each column represents an independent experiment using cells from a different sample of cervix.
Number of wells with immortal cells/the total number of wells examined.